Phase II Results for Abemaciclib in Pretreated HR+/HER2-Negative Breast Cancer

Hope S. Rugo, MD, discusses the final overall analysis of the phase II MONARCH 1 trial, which explored the use of abemaciclib for the treatment of patients with pretreated hormone-receptor (HR)-positive/HER 2-negative advanced breast cancer.